Research Use Only Notice:
Neither full-length thymosin beta-4 nor the Ac-LKKTETQ fragment discussed on this page is FDA-approved for human use in the United States. The materials described here are intended solely for controlled laboratory research and are not intended for personal, clinical, veterinary-treatment, cosmetic, or household use.
This article does not provide reconstitution, dosing, injection, administration, or treatment instructions.
[1]
TB-500 and thymosin beta-4 are often described as if they were the same material. They are not the same chemical structure.
“TB-500” is not a universally reliable product-identity label. In FDA substance records and several anti-doping analytical studies, the name has been associated with Ac-LKKTETQ-OH, the N-terminally acetylated 17–23 fragment of mature Tβ4.

Products sold under the name TB-500 should nevertheless be identified by sequence and batch-specific analytical data.[4][5] Studies of products sold under TB-500 and related names have found that their contents are not always consistent with their labels.[5]
Thymosin beta-4, usually shortened to Tβ4, is a naturally produced peptide linked to the human TMSB4X gene. UniProt lists a 44-amino-acid canonical translation product because the gene product includes an initiator methionine.[2]
During normal processing, this first methionine is removed and the next amino acid, serine, is acetylated. The mature Tβ4 peptide therefore contains 43 amino acids.[3]
In a published chemical analysis, a product labeled TB-500 contained the N-terminally acetylated seven-amino-acid sequence Ac-LKKTETQ. This sequence matches residues 17–23 of mature Tβ4.[4]
This article uses the term defined TB-500 fragment only for Ac-LKKTETQ-OH. The label “TB-500” alone does not prove that a sample contains this exact sequence.
Basic Chemical Differences
| Parameter | Mature Thymosin Beta-4 | Defined TB-500 Fragment |
|---|---|---|
| Type of material | Full mature Tβ4 peptide | Synthetic fragment of Tβ4 residues 17–23 |
| Amino-acid count | 43 | 7 |
| Sequence | Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH | Ac-LKKTETQ-OH |
| Molecular formula | C212H350N56O78S | C38H68N10O14 |
| Average molecular weight | Approximately 4,963 g/mol (monoisotopic: 4,960.49 Da)[6] | Approximately 889.0 g/mol (monoisotopic: ~888.49 Da)[7] |
| CAS number for the listed form | 77591-33-4 | 885340-08-9 |
| N-terminal amino acid | Acetylated serine | Acetylated leucine |
| Relationship to Tβ4 | Contains the complete mature sequence | Contains only residues 17–23 |
The sequence, molecular formula, average and monoisotopic molecular weights, and CAS information for mature Tβ4 are listed in the PubChem timbetasin record (CID 16132341).[6] PubChem separately lists Ac-LKKTETQ-OH with a molecular weight of approximately 889.0 g/mol and CAS number 885340-08-9 (CID 62707662).[7]
Sequence changes, covalent terminal modifications, oxidation, and isotope labelling alter the covalent mass of the peptide. Salt and counterion forms mainly affect the composition and gravimetric peptide content of the supplied material, although counterion or metal adducts may also change the observed m/z in a mass spectrum without changing the calculated neutral peptide mass.
The “Ac-” in Ac-LKKTETQ denotes covalent N-terminal acetylation and should not be confused with an acetate salt form. These values apply to the exact structures shown above and must be verified against the batch-specific COA.
How Full-Length Tβ4 Binds Actin
Actin exists as single units called G-actin and as longer filaments called F-actin. In cell-free laboratory experiments, full-length Tβ4 can bind one G-actin molecule and reduce its addition to an actin filament.[8]
One study using platelet actin reported a dissociation constant of about 0.4–0.7 µM for the full-length Tβ4–actin complex. The same study found that Tβ4 forms a 1:1 complex with monomeric actin under physiological salt conditions, that the Kd is not affected by calcium, and that Tβ4–actin complexes do not elongate actin filaments at either the barbed or the pointed end.[9]
This Kd value should not be presented as a fixed value for every experiment. Reported binding strength changes with the source of actin, the nucleotide attached to actin, the test method, the buffer, the temperature, and other laboratory conditions.
For example, Carlier and colleagues reported that full-length Tβ4 bound MgATP-actin much more strongly than MgADP-actin in an in-vitro biochemical study. The authors described the interaction as being modulated by the ATP/ADP ratio, with implications for the availability of actin monomers for polymerisation.[10]
This shows why a binding value should always be reported together with the test conditions.
Tβ4 is mainly described as an actin-sequestering peptide, but the system is not always simple. At experimental concentrations below approximately 20 µM, Tβ4 behaved as a simple G-actin-sequestering peptide; at higher concentrations (up to 300 µM tested), its depolymerising activity decreased, and low molar proportions of Tβ4–actin complexes were reported to incorporate into F-actin under the tested cell-free conditions.[11]
It is therefore safer to describe Tβ4 as an important regulator of actin availability rather than saying that it always blocks actin polymerization in exactly the same way.
The LKKTETQ Region Is Important but Not Sufficient on Its Own
The seven-amino-acid LKKTETQ region is an important part of the Tβ4 actin-binding site. However, it is not the only part of Tβ4 that contacts actin.
Mutational studies by Van Troys and colleagues found that amino acids in the N-terminal region of Tβ4, especially residues 1–16, also help bind actin. The central sequence around residues 17–22 forms another important contact area.[12]
Another study found that a full-length Tβ4 variant missing residues 17–23 no longer showed detectable G-actin binding in the reported assay.[13]
This result shows that residues 17–23 are needed for normal full-length Tβ4 binding. It does not prove that the isolated seven-amino-acid fragment has the same binding strength or the same effect as full-length Tβ4.
A structural study by Irobi and colleagues used a stabilised gelsolin-domain-1–Tβ4 hybrid complex, together with modelling of full-length Tβ4, and indicated that Tβ4 contacts more than one region of the actin surface. The complete interaction therefore involves a larger area than the LKKTETQ sequence alone.[14]
What Is Known About the Defined TB-500 Fragment
Direct research on Ac-LKKTETQ is much more limited than research on full-length Tβ4. Many papers cited in discussions of TB-500 actually evaluated full-length Tβ4, unacetylated LKKTETQ, other Tβ4-derived fragments, or related peptides, rather than the defined Ac-LKKTETQ fragment itself.
A 2024 study by Rahaman and colleagues measured Ac-LKKTETQ and several of its breakdown products in laboratory systems and in a standardised rat metabolism model, using UHPLC-Q-Exactive Orbitrap MS/MS. The study also tested the parent fragment and its breakdown products in a fibroblast scratch assay.
Under the reported conditions, only the shorter metabolite Ac-LKKTE showed a significant change in the scratch-assay result.[15]
This finding does not prove that Ac-LKKTETQ has no laboratory activity. It shows that the parent fragment, its metabolites, and full-length Tβ4 should be tested as separate materials.
Their results should not be combined as if they were the same molecule.
Why Full-Length Tβ4 Studies Cannot Automatically Be Used for TB-500
Full-length Tβ4 and Ac-LKKTETQ differ in several basic ways:
- They have different sequence lengths (43 vs 7 residues).
- They have different molecular weights (4,963 vs 889 g/mol).
- They have different charge patterns.
- They expose different surfaces for molecular binding.
- They may break down into different products.
- They may behave differently in buffers, cell cultures, and biological samples.
For these reasons, the following statements should not be used without direct comparative data:
- “TB-500 has the same actin-binding strength as Tβ4.”
- “TB-500 produces every laboratory effect reported for Tβ4.”
- “Any study that used Tβ4 is also a TB-500 study.”
- “LKKTETQ is the only part of Tβ4 that binds actin.”
- “Every product labeled TB-500 contains pure Ac-LKKTETQ.”
A more accurate statement is:
Ac-LKKTETQ matches residues 17–23 of Tβ4 and contains an important part of the Tβ4 actin-binding region. Because full-length Tβ4 also uses amino acids outside this sequence, the isolated fragment must be tested separately.
How to Check the Identity of a Research Sample
A product name is not enough to confirm identity. A research sample should be described by its complete sequence, terminal modifications, salt or counterion form, and batch-specific analytical results.
Liquid chromatography–mass spectrometry can help distinguish full-length Tβ4 from Ac-LKKTETQ because their molecular masses are very different. When comparing LC-MS data with database values, researchers should note that average molecular weight (4,963 g/mol for Tβ4; 889.0 g/mol for Ac-LKKTETQ) and monoisotopic mass (4,960.49 Da; ~888.49 Da) represent different quantities.
A report should show the observed ion, assigned charge state, theoretical mass, and calculated or deconvoluted mass. It should not simply write “4,963 m/z” as if molecular weight and m/z were always the same value.
More than one peak in a chromatogram or mass spectrum does not automatically mean only degradation or deliberate mixing. Other possible causes include:
- Shortened peptide sequences;
- Incomplete N-terminal acetylation;
- Oxidation, especially at the methionine in full-length Tβ4;
- Sodium, potassium, acetate, or trifluoroacetate adducts;
- Peptide-synthesis by-products;
- Different salt forms;
- Sample handling changes;
- Instrument-source fragmentation;
- Actual degradation or mixed contents.
When the exact sequence matters, intact mass should be combined with a suitable chromatographic method and, when needed, sequence-confirming tandem mass spectrometry.
How to Read a Peptide COA
A certificate of analysis, or COA, should apply to the exact batch being supplied. A chromatogram from another batch or a general example is not batch-specific evidence.
HPLC purity and peptide content are not the same measurement. An HPLC area percentage mainly shows how much of the detected chromatogram belongs to the main peak under that specific method. It does not automatically measure:
- Water content;
- Counterions or salts;
- Residual solvents;
- Inorganic material;
- Total peptide content by weight;
- Sequence accuracy;
- Biological activity.
A mass result close to the expected value supports identity, but mass alone cannot prove complete sequence accuracy, purity, peptide content, or the absence of related impurities.
FDA’s Q6A analytical guidance treats identity, assay or content, impurities, and residual solvents as separate quality questions. It also explains that one chromatographic retention time is normally not specific enough for identity and that combined methods, such as chromatography with mass spectrometry, can provide stronger evidence.[16]
Q6A is written for regulated drug substances and products, not as a universal COA template for every research peptide. However, the basic testing principle is still useful: identity, purity, content, water, solvents, and impurities should not be treated as one result.
A useful research-peptide COA may include:
- Batch or lot number;
- Full amino-acid sequence;
- N-terminal and C-terminal modifications;
- Salt or counterion form;
- Theoretical average and monoisotopic molecular mass;
- Observed mass, charge state, and mass error (ppm);
- HPLC method details (column, mobile phase, gradient, wavelength) and purity result;
- Peptide-content result, if tested, with method stated;
- Water or loss-on-drying result;
- Residual-solvent result, when relevant;
- Test date and authorised review.
An FDA substance name or UNII number identifies a substance in a database. It does not mean that the substance or a product containing it has been reviewed or approved by FDA.[17]
How to Design a Fair Laboratory Comparison
A fair comparison between full-length Tβ4 and Ac-LKKTETQ should use clearly identified materials and the same test conditions.
- Confirm both materials: Record the sequence, modifications, salt form, mass result, HPLC result, and batch number.
- Use molar concentration: Equal weight does not mean an equal number of molecules because the two peptides have very different molecular weights (4,963 vs 889 g/mol).
- Use proper controls: Include untreated, solvent, assay-positive, and suitable sequence controls.
- Test more than one concentration: A single concentration cannot show relative binding strength or potency.
- Test more than one time point: The parent peptide and its breakdown products may behave differently over time.
- Separate different questions: Direct actin binding, actin polymerization, cell movement, cell viability, and signalling markers are different measurements.
- Name the model: State whether the result came from a purified-protein assay, an in-vitro cell system, or a standardised laboratory animal model.
Results should be limited to the exact model used. A result from a purified-protein test does not prove a cell effect, and a result from an in-vitro cell assay does not prove an effect outside that model.
Anti-Doping Status
The World Anti-Doping Agency’s 2026 Prohibited List took effect on January 1, 2026. The list includes thymosin beta-4 and its derivatives, such as TB-500, within the S2.3 growth-factor category and is prohibited at all times in sport.[18]
This anti-doping classification is a sports rule. It does not prove that a product label is chemically correct, that a sample is pure, or that the short fragment has the same laboratory effects as full-length Tβ4.
Key Points
- Mature Tβ4 is a 43-amino-acid N-acetylated peptide. The UniProt canonical translation product contains 44 amino acids, including the initiator methionine.
- The defined TB-500 fragment discussed in analytical studies is Ac-LKKTETQ-OH.
- Ac-LKKTETQ contains only Tβ4 residues 17–23.
- The LKKTETQ region is important for actin binding, but other Tβ4 residues (especially residues 1–16) also take part.
- The full-length Tβ4 Kd of 0.4–0.7 µM was measured with platelet actin and should not be assigned to Ac-LKKTETQ without direct testing.
- Research using full-length Tβ4 is not automatically evidence for the TB-500 fragment.
- A product name, HPLC percentage, or mass result alone is not enough for complete batch identification.
- All conclusions must stay within the purified-protein, in-vitro cell, or standardised laboratory model that was actually tested.
References
- U.S. Food and Drug Administration. GenoGenix LLC Warning Letter, January 20, 2026.
- UniProtKB P62328. Thymosin beta-4, Homo sapiens (canonical translation product: 44 aa; mature peptide: 43 aa after initiator Met removal and N-acetylation).
- Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin β4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci USA. 1981;78(2):1162–1166.
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17–23 fragment of thymosin beta-4 identified in TB-500. Drug Test Anal. 2012;4(9):733–738.
- Delcourt V, Garcia M, Chabot B, et al. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. Drug Test Anal. 2023;15(4):388–401.
- PubChem CID 16132341. Timbetasin (thymosin β4): C212H350N56O78S, 4,963 g/mol (avg), 4,960.49 Da (monoisotopic).
- PubChem CID 62707662. TB-500 (Ac-LKKTETQ-OH): C38H68N10O14, 889.0 g/mol (avg).
- Safer D, Elzinga M, Nachmias VT. Thymosin β4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem. 1991;266(7):4029–4032.
- Weber A, Nachmias VT, Pennise CR, Pring M, Safer D. Interaction of thymosin β4 with muscle and platelet actin: implications for actin sequestration in resting platelets. Biochemistry. 1992;31(27):6179–6185.
- Carlier MF, Jean C, Rieger KJ, Lenfant M, Pantaloni D. Modulation of the interaction between G-actin and thymosin β4 by the ATP/ADP ratio: possible implication in the regulation of actin dynamics. Proc Natl Acad Sci USA. 1993;90(11):5034–5038.
- Pantaloni D, Carlier MF. How profilin promotes actin filament assembly in the presence of thymosin β4. Cell. 1993;75(5):1007–1014. [Note: correct PMID for this paper is 8222603; the cited PMID 8621582 refers to Carlier et al. J Biol Chem 1996 on Tβ4–actin complex incorporation into F-actin at high concentration.]
- Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C. The actin binding site of thymosin β4 mapped by mutational analysis. EMBO J. 1996;15(2):201–210.
- Zoubek RE, Hannappel E. Influence of the N terminus and the actin-binding motif of thymosin β4 on its interaction with G-actin. Ann N Y Acad Sci. 2007;1112:435–441.
- Irobi E, Aguda AH, Larsson M, et al. Structural basis of actin sequestration by thymosin-β4: implications for WH2 proteins. EMBO J. 2004;23(18):3599–3608.
- Rahaman MM, Nguyen TT, Page K, et al. Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive Orbitrap MS/MS and their screening by wound-healing activities in-vitro. J Chromatogr B. 2024;1237:124002.
- U.S. Food and Drug Administration. ICH Q6A Specifications: Test Procedures and Acceptance Criteria.
- U.S. Food and Drug Administration Global Substance Registration System. TB-500, UNII QHK6Z47GTG.
- World Anti-Doping Agency. 2026 Prohibited List (effective 1 January 2026). Thymosin β4 and derivatives, e.g. TB-500, prohibited under S2.3.Research Use Only Disclaimer
Research Use Only: The products described on this page are supplied for laboratory research use only and are not intended for human or veterinary use. This article is provided for informational context regarding published laboratory research and general analytical and handling considerations, and does not constitute medical, clinical, veterinary guidance or treatment advice.
Need to work out which form is actually in a vial or blend? See our guide to TB-500 fragment vs full, covering label wording, intact-mass checks and a COA checklist.
Related research: TB-500 Fragment vs Full: Ac-LKKTETQ vs Thymosin Beta-4 (Identity, MS & COA Guide); TB-500 (Thymosin Beta-4); TB-500; What Is Thymosin Alpha-1.